In conclusion, in the context of first-line therapy for patients with EGFR-mutated oligo-organ metastatic NSCLC, third-generation EGFR TKI+TRT enhanced PFS and OS more prominently than did EGFR TKI alone. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.